Predicting Benefit From Olaparib Maintenance in Metastatic Pancreatic Cancer: The POLO Trial

Based on results from the POLO trial,1,2 the BRACAnalysis CDx assay (Myriad Genetics) changed into able to pick outpatients with metastatic pancreatic most cancers who benefitted from upkeep therapy with the poly [ADP ribose] polymerase (PARP) inhibitor olaparib, in line with press bulletins released on February 26, 2019.1, three

The POLO observe is a section 3, randomized, controlled trial of olaparib monotherapy in 154 sufferers with metastatic pancreatic adenocarcinoma (with a disease that had now not progressed following first-line platinum-based chemotherapy) who have been randomly assigned (three:2) to receive twice-day by day management of 300 mg of olaparib or placebo.1,2

All patients who were enrolled within the examination had a deleterious or suspected deleterious germline BRCA1/2 mutation diagnosed by way of the BRACAnalysis CDx assay. The number one quit factor of the POLO trial becomes progression-loose survival, with ordinary survival, average response fee, protection, and health-associated first-class of lifestyles included as secondary give-up elements.

Results from the POLO trial showed that it met its number one-stop point of statistically significant development in PFS. At the same time, the olaparib arm becomes as compared with the placebo arm. Also, olaparib’s protection and tolerability profiles have been similar to results observed in preceding trials of this agent in different cancers.1

“This is the tremendous primary phase three trial of any PARP inhibitor in germline BRCA-mutated metastatic pancreatic cancer, a devastating ailment with pressing unmet need. The outcomes of POLO offer similar evidence of the clinical benefit of [olaparib] across a variety of BRCA-mutated tumor types. We will talk about these consequences with worldwide health authorities as soon as possible,” stated José Baselga, govt vice president, studies and development, oncology at AstraZeneca.

The BRACAnalysis CDx test has formerly obtained approval from the American Food and Drug Administration (FDA) as an accomplice diagnostic assay for figuring out sufferers with advanced breast and ovarian cancers who are candidates for the PARP inhibitor olaparib. Three

References

AstraZeneca. Lynparza extensively not on time ailment progression as a 1st-line maintenance remedy in germline BRCA-mutated metastatic pancreatic most cancers [press release]. Published on February 26, 2019. Accessed February 28, 2019.
ClinicalTrials.Gov Identifier: NCT02184195. Olaparib in gBRCA mutated pancreatic cancer whose disorder has no longer improved on first-line platinum-based chemotherapy (POLO). Updated January 29, 2019. Accessed February 28, 2019.
Myriad. Myriad’s BRACAnalysis CDx® check conclusively diagnosed patients with metastatic pancreatic cancer who benefitted from treatment with olaparib [press release]. Published on February 26, 2019. Accessed February 28, 2019.